Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis

Autor: Anders N Myken, Bjørn H Ebdrup, Mikkel E Sørensen, Brian V Broberg, Martin W Skjerbæk, Birte Y Glenthøj, Jens Lykkesfeldt, Mette Ø Nielsen
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Myken, A N, Ebdrup, B H, Sørensen, M E, Broberg, B V, Skjerbæk, M W, Glenthøj, B Y, Lykkesfeldt, J & Nielsen, M 2022, ' Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis ', The international journal of neuropsychopharmacology, vol. 25, no. 8, pp. 613-618 . https://doi.org/10.1093/ijnp/pyac029
DOI: 10.1093/ijnp/pyac029
Popis: Low levels of vitamin C have been observed in patients with schizophrenia and psychosis, and vitamin C may affect the dopaminergic system. Likewise, antipsychotic medication modulates striatal dopamine D2 receptors. We measured vitamin C levels in 52 patients with first-episode psychoses (24 females, age 23.1 ± 5.2 years) and 57 matched HCs (20 females, age 22.7 ± 4.3 years) before and after 6 weeks where patients received aripiprazole monotherapy (mean dose 10.4 mg ± 4.8 mg). At baseline, patients displayed lower levels of vitamin C (57.4 ± 25.9 µM) than controls (72.7 ± 21.4 µM) (t = 3.4, P = .001). Baseline symptoms and vitamin C levels were not correlated. Higher baseline vitamin C levels were associated with more improvement in negative symptoms (n = 39, R2 = 0.20, F = 8.2, P = .007), but not with age, sex, or p-aripiprazole. Because negative symptoms are generally considered challenging to alleviate, a potential adjunctive effect of vitamin C on treatment response should be tested in future randomized clinical trials.
Databáze: OpenAIRE